Search results
5 lip 2017 · A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax ®) or brand alendronate (Fosamax ®) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period. Endpoints included bone mineral density (BMD) changes at ...
31 maj 2012 · According to the FDA analysis of the FLEX trial, the rates of vertebral and nonvertebral osteoporotic fractures were similar whether participants continued to receive alendronate (Fosamax) for up...
Alendronate (syn. alendronic acid, alendronate sodium) is available in tablet (Fosamax, Ostemax), effervescent tablet (Binosto), and oral solution (Fosamax) forms, taken daily or weekly. The same doses of different alendronate formulations are bioequivalent [23,35].
1 lip 2017 · Purpose The aim of this study was to evaluate the bioequivalence of a generic product 70 mg alendronate sodium tablets with the reference product Fosamax® 70 mg tablet.
The mean persistence of oral bisphosphonates for 6 months, 1 year and 2 years ranged from 34.8% to 71.3%, 17.7% to 74.8% and 12.9% to 72.0%, respectively. The mean medication possession ratio ranged from 28.2% to 84.5%, 23% to 50%, 27.2% to 46% over 1 year, 2 years and 3 years, respectively.
17 maj 2021 · In this multicenter prospective, observational, postauthorization safety study conducted in Italy and Spain, postmenopausal women (PMW) with osteoporosis (naïve to bisphosphonates) were treated weekly with a buffered soluble alendronate 70 mg effervescent (ALN‐EFF) tablet (Binosto®) and followed for 12 ± 3 months.
21 lip 2011 · Purpose: The aim of this study was to evaluate the bioequivalence of a generic product 70 mg alendronate sodium tablets with the reference product Fosamax® 70 mg tablet. Materials and methods: A single-center, open-label, randomized, three-period, three-sequence, reference-replicated crossover study was performed in 36 healthy Chinese male
